Skip to main content
Erschienen in:

04.09.2024 | Original Article

The coincidence of multiple sclerosis and primary vasculitis; from the bench of pathology to the bedside of treatment: a systematic review of case reports

verfasst von: Melika Arab Bafrani, Hassan Asadigandomani, Naghmeh Abbasi Kasbi, Hora Heidari, Sharareh Eskandarieh

Erschienen in: Neurological Sciences | Ausgabe 1/2025

Einloggen, um Zugang zu erhalten

Abstract

Introduction

Multiple sclerosis (MS) is a chronic, disabling neurodegenerative disease, leads to reduced quality of life. The increasing prevalence of MS around the world and its comorbidities increase its burden. Primary vasculitis subtypes, one of autoimmune diseases with different prevalence in different ages and genders, should be considered one of the important differential diagnosis in patients with MS. This study aims to verify the relationship between MS and primary vasculitis by conducting a systematic review.

Method

We searched PubMed, Scopus, EMBASE, Web of Science, and Google Scholar, from January 1974 to July 2023. We included original articles that reported characteristics of patients involved with any type of Primary Vasculitis with MS.

Result

From an initial 816 publications, 18 studies consisting of 18 individual patients from 14 countries with confirmed MS and one of different subtypes of primary vasculitis met the inclusion criteria. The female/male ratio was 0.38:1, the mean (SD) age was 40.44 (14.37) years with the range of 16 to 70 years old, and the relapsing/progressive ratio was 1.57:1. Most of them, 14 (77%) experienced MS before vasculitis, and mostly received Corticosteroids, interferon, cyclophosphamide, Glatiramer acetate as MS treatment. The concurrence of Takayasu Arteritis (2 cases), Polyarteritis Nodosa (2 cases), Churg-Strauss Syndrome (1 case), Wegener’s Granulomatosis (2 cases), Microscopic Polyangiitis (1 case), Cutaneous leukocytoclastic vasculitis (5 cases), Good pasture’s disease (5 cases) were reported with MS.

Conclusion

Our study suggested that different primary vasculitis can be an important comorbidity of MS and can mimic its symptoms and MRI. Any atypical syndrome for PwMS, whether clinical or radiological, must be evaluated in terms of other differential diagnoses including vasculitis.
Literatur
1.
Zurück zum Zitat Ghasemi N, Razavi S, Nikzad E (2017) Multiple sclerosis: pathogenesis, symptoms, diagnoses and cell-based therapy. Cell J (Yakhteh) 19(1):1 Ghasemi N, Razavi S, Nikzad E (2017) Multiple sclerosis: pathogenesis, symptoms, diagnoses and cell-based therapy. Cell J (Yakhteh) 19(1):1
2.
Zurück zum Zitat Walton C, King R, Rechtman L, Kaye W, Leray E, Marrie RA, Robertson N, La Rocca N, Uitdehaag B, van Der Mei I, Wallin M (2020) Rising prevalence of multiple sclerosis worldwide: insights from the Atlas of MS. Multiple Scler J 26(14):1816–1821CrossRef Walton C, King R, Rechtman L, Kaye W, Leray E, Marrie RA, Robertson N, La Rocca N, Uitdehaag B, van Der Mei I, Wallin M (2020) Rising prevalence of multiple sclerosis worldwide: insights from the Atlas of MS. Multiple Scler J 26(14):1816–1821CrossRef
3.
Zurück zum Zitat Jewells VL, Latchaw RE (2020) CNS Vasculitis-An overview of this multiple sclerosis Mimic: clinical and MRI implications. Semin Ultrasound CT MR 41(3):296–308PubMedCrossRef Jewells VL, Latchaw RE (2020) CNS Vasculitis-An overview of this multiple sclerosis Mimic: clinical and MRI implications. Semin Ultrasound CT MR 41(3):296–308PubMedCrossRef
4.
Zurück zum Zitat Guillevin L, Dörner T (2007) Vasculitis: mechanisms involved and clinical manifestations. Arthritis Res Therapy 9:1–9CrossRef Guillevin L, Dörner T (2007) Vasculitis: mechanisms involved and clinical manifestations. Arthritis Res Therapy 9:1–9CrossRef
5.
Zurück zum Zitat Weyand CM, Goronzy JJ (2003) Medium-and large-vessel vasculitis. N Engl J Med 349(2):160–169PubMedCrossRef Weyand CM, Goronzy JJ (2003) Medium-and large-vessel vasculitis. N Engl J Med 349(2):160–169PubMedCrossRef
6.
Zurück zum Zitat Strunk D, Schmidt-Pogoda A, Beuker C, Milles LS, Korsukewitz C, Meuth SG, Minnerup J (2019) Biomarkers in vasculitides of the nervous system. Front Neurol 10:591PubMedPubMedCentralCrossRef Strunk D, Schmidt-Pogoda A, Beuker C, Milles LS, Korsukewitz C, Meuth SG, Minnerup J (2019) Biomarkers in vasculitides of the nervous system. Front Neurol 10:591PubMedPubMedCentralCrossRef
8.
Zurück zum Zitat Burg LC, Karakostas P, Behning C, Brossart P, Kermani TA, Schäfer VS (2023) Prevalence and characteristics of giant cell arteritis in patients with newly diagnosed polymyalgia rheumatica–a prospective cohort study. Therapeutic Adv Musculoskelet Disease 15:1759720X221149963CrossRef Burg LC, Karakostas P, Behning C, Brossart P, Kermani TA, Schäfer VS (2023) Prevalence and characteristics of giant cell arteritis in patients with newly diagnosed polymyalgia rheumatica–a prospective cohort study. Therapeutic Adv Musculoskelet Disease 15:1759720X221149963CrossRef
9.
Zurück zum Zitat Ciofalo A, Gulotta G, Iannella G, Pasquariello B, Manno A, Angeletti D, Pace A, Greco A, Altissimi G, de Vincentiis M, Magliulo G (2019) Giant cell arteritis (GCA): Pathogenesis, clinical aspects and treatment approaches. Curr Rheumatol Rev 15(4):259–268PubMedCrossRef Ciofalo A, Gulotta G, Iannella G, Pasquariello B, Manno A, Angeletti D, Pace A, Greco A, Altissimi G, de Vincentiis M, Magliulo G (2019) Giant cell arteritis (GCA): Pathogenesis, clinical aspects and treatment approaches. Curr Rheumatol Rev 15(4):259–268PubMedCrossRef
10.
Zurück zum Zitat Dedushi K, Hyseni F, Musa J, Rahman M, Saliaj K, Vokshi V, Shatri J, Siddik AB, Ahsan E, Ikram S, Abdullahu B (2021) MRI diagnosis of Takayasu arteritis in a young woman. Radiol Case Rep 16(12):3915–3919PubMedPubMedCentralCrossRef Dedushi K, Hyseni F, Musa J, Rahman M, Saliaj K, Vokshi V, Shatri J, Siddik AB, Ahsan E, Ikram S, Abdullahu B (2021) MRI diagnosis of Takayasu arteritis in a young woman. Radiol Case Rep 16(12):3915–3919PubMedPubMedCentralCrossRef
11.
Zurück zum Zitat Donnelly R, London NJ (eds) (2009) ABC of arterial and venous disease. Wiley. Apr 8 Donnelly R, London NJ (eds) (2009) ABC of arterial and venous disease. Wiley. Apr 8
12.
Zurück zum Zitat Regola F, Uzzo M, Toniati P, Trezzi B, Sinico RA, Franceschini F (2022) Novel therapies in Takayasu arteritis. Front Med 8:814075CrossRef Regola F, Uzzo M, Toniati P, Trezzi B, Sinico RA, Franceschini F (2022) Novel therapies in Takayasu arteritis. Front Med 8:814075CrossRef
13.
Zurück zum Zitat Agarwal S, Agrawal DK (2017) Kawasaki disease: etiopathogenesis and novel treatment strategies. Expert Rev Clin Immunol 13(3):247–258PubMedCrossRef Agarwal S, Agrawal DK (2017) Kawasaki disease: etiopathogenesis and novel treatment strategies. Expert Rev Clin Immunol 13(3):247–258PubMedCrossRef
14.
Zurück zum Zitat Janssen HL, van Zonneveld M, van Nunen AB, Niesters HG, Schalm SW, de Man RA (2004) Polyarteritis nodosa associated with hepatitis B virus infection. The role of antiviral treatment and mutations in the hepatitis B virus genome. Eur J Gastroenterol Hepatol 16(8):801–807PubMedCrossRef Janssen HL, van Zonneveld M, van Nunen AB, Niesters HG, Schalm SW, de Man RA (2004) Polyarteritis nodosa associated with hepatitis B virus infection. The role of antiviral treatment and mutations in the hepatitis B virus genome. Eur J Gastroenterol Hepatol 16(8):801–807PubMedCrossRef
15.
Zurück zum Zitat Stanson AW, Friese JL, Johnson CM, McKusick MA, Breen JF, Sabater EA, Andrews JC (2001) Polyarteritis nodosa: spectrum of angiographic findings. Radiographics 21(1):151–159PubMedCrossRef Stanson AW, Friese JL, Johnson CM, McKusick MA, Breen JF, Sabater EA, Andrews JC (2001) Polyarteritis nodosa: spectrum of angiographic findings. Radiographics 21(1):151–159PubMedCrossRef
16.
Zurück zum Zitat Russe-Russe JR, Pellegrini JR Jr, Alvarez-Betancourt A, Munshi RF, Anand P, Betancourt AA, Munshi RF (2021) Fulminant anti-neutrophil cytoplasmic antibody-associated vasculitis after 10 years of hydralazine use. Cureus. ;13(10) Russe-Russe JR, Pellegrini JR Jr, Alvarez-Betancourt A, Munshi RF, Anand P, Betancourt AA, Munshi RF (2021) Fulminant anti-neutrophil cytoplasmic antibody-associated vasculitis after 10 years of hydralazine use. Cureus. ;13(10)
17.
Zurück zum Zitat Morita TC, Criado PR, Criado RF, Trés GF, Sotto MN (2020) Update on vasculitis: overview and relevant dermatological aspects for the clinical and histopathological diagnosis-part II. An Bras Dermatol 95:493–507PubMedPubMedCentralCrossRef Morita TC, Criado PR, Criado RF, Trés GF, Sotto MN (2020) Update on vasculitis: overview and relevant dermatological aspects for the clinical and histopathological diagnosis-part II. An Bras Dermatol 95:493–507PubMedPubMedCentralCrossRef
18.
Zurück zum Zitat Greco A, Rizzo MI, De Virgilio A, Gallo A, Fusconi M, Ruoppolo G, Altissimi G, De Vincentiis M (2015) Churg–Strauss syndrome. Autoimmun rev 14(4):341–348PubMedCrossRef Greco A, Rizzo MI, De Virgilio A, Gallo A, Fusconi M, Ruoppolo G, Altissimi G, De Vincentiis M (2015) Churg–Strauss syndrome. Autoimmun rev 14(4):341–348PubMedCrossRef
19.
Zurück zum Zitat Greco A, Marinelli C, Fusconi M, Macri GF, Gallo A, De Virgilio A, Zambetti G, de Vincentiis M (2016) Clinic manifestations in granulomatosis with polyangiitis. Int J ImmunoPathol Pharmacol 29(2):151–159PubMedCrossRef Greco A, Marinelli C, Fusconi M, Macri GF, Gallo A, De Virgilio A, Zambetti G, de Vincentiis M (2016) Clinic manifestations in granulomatosis with polyangiitis. Int J ImmunoPathol Pharmacol 29(2):151–159PubMedCrossRef
20.
Zurück zum Zitat Durel CA, Sinico RA, Teixeira V, Jayne D, Belenfant X, Marchand-Adam S, Pugnet G, Gaultier J, Le Gallou T, Titeca-Beauport D, Agard C (2021) Renal involvement in eosinophilic granulomatosis with polyangiitis (EGPA): a multicentric retrospective study of 63 biopsy-proven cases. Rheumatology 60(1):359–365PubMedCrossRef Durel CA, Sinico RA, Teixeira V, Jayne D, Belenfant X, Marchand-Adam S, Pugnet G, Gaultier J, Le Gallou T, Titeca-Beauport D, Agard C (2021) Renal involvement in eosinophilic granulomatosis with polyangiitis (EGPA): a multicentric retrospective study of 63 biopsy-proven cases. Rheumatology 60(1):359–365PubMedCrossRef
21.
Zurück zum Zitat Lababidi MH, Odigwe C, Okolo C, Elhassan A, Iroegbu N Microscopic polyangiitis causing diffuse alveolar hemorrhage and rapidly progressive glomerulonephritis. InBaylor University Medical Center Proceedings 2015 Oct 1 (Vol. 28, No. 4, pp. 469–471). Taylor & Francis Lababidi MH, Odigwe C, Okolo C, Elhassan A, Iroegbu N Microscopic polyangiitis causing diffuse alveolar hemorrhage and rapidly progressive glomerulonephritis. InBaylor University Medical Center Proceedings 2015 Oct 1 (Vol. 28, No. 4, pp. 469–471). Taylor & Francis
22.
Zurück zum Zitat Walters GD, Willis NS, Craig JC (2010) Interventions for renal vasculitis in adults. A systematic review. BMC Nephrol 11:1–23CrossRef Walters GD, Willis NS, Craig JC (2010) Interventions for renal vasculitis in adults. A systematic review. BMC Nephrol 11:1–23CrossRef
23.
Zurück zum Zitat Johnson EF, Lehman JS, Wetter DA, Lohse CM, Tollefson MM (2015) Henoch-Schönlein purpura and systemic disease in children: retrospective study of clinical findings, histopathology and direct immunofluorescence in 34 paediatric patients. Br J Dermatol 172(5):1358–1363PubMedCrossRef Johnson EF, Lehman JS, Wetter DA, Lohse CM, Tollefson MM (2015) Henoch-Schönlein purpura and systemic disease in children: retrospective study of clinical findings, histopathology and direct immunofluorescence in 34 paediatric patients. Br J Dermatol 172(5):1358–1363PubMedCrossRef
24.
Zurück zum Zitat Sestan M, Jelusic M (2023) Diagnostic and management strategies of IgA Vasculitis Nephritis/Henoch-Schönlein Purpura Nephritis in Pediatric patients: current perspectives. Pediatr Health Med Ther 14:89–98CrossRef Sestan M, Jelusic M (2023) Diagnostic and management strategies of IgA Vasculitis Nephritis/Henoch-Schönlein Purpura Nephritis in Pediatric patients: current perspectives. Pediatr Health Med Ther 14:89–98CrossRef
25.
Zurück zum Zitat Braun GS, Horster S, Wagner KS, Ihrler S, Schmid H (2007) Cryoglobulinaemic vasculitis: classification and clinical and therapeutic aspects. Postgrad Med J 83(976):87–94PubMedPubMedCentralCrossRef Braun GS, Horster S, Wagner KS, Ihrler S, Schmid H (2007) Cryoglobulinaemic vasculitis: classification and clinical and therapeutic aspects. Postgrad Med J 83(976):87–94PubMedPubMedCentralCrossRef
27.
Zurück zum Zitat McAdoo SP, Pusey CD (2017) Anti-glomerular basement membrane disease. Clin J Am Soc Nephrology: CJASN 12(7):1162CrossRef McAdoo SP, Pusey CD (2017) Anti-glomerular basement membrane disease. Clin J Am Soc Nephrology: CJASN 12(7):1162CrossRef
28.
Zurück zum Zitat Page MJ, McKenzie JE, Bossuyt PM et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 372:n71 Published 2021 Mar 29PubMedPubMedCentralCrossRef Page MJ, McKenzie JE, Bossuyt PM et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 372:n71 Published 2021 Mar 29PubMedPubMedCentralCrossRef
33.
Zurück zum Zitat Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A (2016) Rayyan—a web and mobile app for systematic reviews. Syst Reviews 5:1–0CrossRef Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A (2016) Rayyan—a web and mobile app for systematic reviews. Syst Reviews 5:1–0CrossRef
34.
Zurück zum Zitat Murad MH, Sultan S, Haffar S, Bazerbachi F (2018) Methodological quality and synthesis of case series and case reports. BMJ evidence-based medicine. Feb 2 Murad MH, Sultan S, Haffar S, Bazerbachi F (2018) Methodological quality and synthesis of case series and case reports. BMJ evidence-based medicine. Feb 2
35.
Zurück zum Zitat Diamantopoulos AP, Hetland H, Hansen AE, Myklebust G (2012) Severe deterioration of newly diagnosed Takayasu arteritis in a patient re-treated with interferon beta-1α for concomitant longstanding multiple sclerosis. Mod Rheumatol 22(3):474–478PubMedCrossRef Diamantopoulos AP, Hetland H, Hansen AE, Myklebust G (2012) Severe deterioration of newly diagnosed Takayasu arteritis in a patient re-treated with interferon beta-1α for concomitant longstanding multiple sclerosis. Mod Rheumatol 22(3):474–478PubMedCrossRef
36.
Zurück zum Zitat Brashear A, Pascuzzi RM (1992) Takayasu’s arteritis and multiple sclerosis. J Neuroimag 2:36–38CrossRef Brashear A, Pascuzzi RM (1992) Takayasu’s arteritis and multiple sclerosis. J Neuroimag 2:36–38CrossRef
37.
Zurück zum Zitat Matsuda KM, Koguchi A, Toyama T, Sakuishi K, Kobayashi M, Miura S, Miyazaki M, Suga H, Asano Y, Toda T, Sato S (2020) Concurrence of polyarteritis nodosa and multiple sclerosis. J Eur Acad Dermatology Venereology: JEADV 34(4):e188–e191CrossRef Matsuda KM, Koguchi A, Toyama T, Sakuishi K, Kobayashi M, Miura S, Miyazaki M, Suga H, Asano Y, Toda T, Sato S (2020) Concurrence of polyarteritis nodosa and multiple sclerosis. J Eur Acad Dermatology Venereology: JEADV 34(4):e188–e191CrossRef
38.
Zurück zum Zitat Waisburg H, Meloff KL, Buncic R (1974) Polyarteritis nodosa complicated by a multiple sclerosis like syndrome. Can J Neurol Sci 1(4):250–252PubMedCrossRef Waisburg H, Meloff KL, Buncic R (1974) Polyarteritis nodosa complicated by a multiple sclerosis like syndrome. Can J Neurol Sci 1(4):250–252PubMedCrossRef
39.
Zurück zum Zitat Sarkar P, Ibitoye RT, Promnitz DA (2011) Churg–Strauss syndrome in a patient previously diagnosed with multiple sclerosis. Case Rep 2011:bcr0620114300 Sarkar P, Ibitoye RT, Promnitz DA (2011) Churg–Strauss syndrome in a patient previously diagnosed with multiple sclerosis. Case Rep 2011:bcr0620114300
40.
Zurück zum Zitat Aldasoro-Cáceres V, Aldasoro-Cáceres I, Pérez-Moreiras JV, Murié-Fernández M, Ibáñez-Bosch R (2014) C-ANCA positive necrotising scleritis and multiple sclerosis compatible with ocular Wegener: treatment with rituximab. Arch De La Sociedad Española De Oftalmología (English Edition) 89(1):31–34 Aldasoro-Cáceres V, Aldasoro-Cáceres I, Pérez-Moreiras JV, Murié-Fernández M, Ibáñez-Bosch R (2014) C-ANCA positive necrotising scleritis and multiple sclerosis compatible with ocular Wegener: treatment with rituximab. Arch De La Sociedad Española De Oftalmología (English Edition) 89(1):31–34
41.
Zurück zum Zitat Sauer EM, Schliep S, Manger B, Lee DH, Linker RA (2018) Microscopic polyangiitis after alemtuzumab treatment in relapsing-remitting MS. Neurology-Neuroimmunology Neuroinflammation. ;5(5) Sauer EM, Schliep S, Manger B, Lee DH, Linker RA (2018) Microscopic polyangiitis after alemtuzumab treatment in relapsing-remitting MS. Neurology-Neuroimmunology Neuroinflammation. ;5(5)
42.
Zurück zum Zitat Garten L, Edwards K, Lezcano C, Spiro J, Siuta J, Belcher S Case report: leukocytoclastic vasculitis in an MS patient following alemtuzumab treatment (P5. 403) Garten L, Edwards K, Lezcano C, Spiro J, Siuta J, Belcher S Case report: leukocytoclastic vasculitis in an MS patient following alemtuzumab treatment (P5. 403)
43.
Zurück zum Zitat Durães J, Gonçalo M, Sousa L, Macário MC (2019) Hypocomplementemic urticarial vasculitis and multiple sclerosis: a rare association or an atypical presentation? Multiple Scler Relat Disorders 30:244–246CrossRef Durães J, Gonçalo M, Sousa L, Macário MC (2019) Hypocomplementemic urticarial vasculitis and multiple sclerosis: a rare association or an atypical presentation? Multiple Scler Relat Disorders 30:244–246CrossRef
44.
Zurück zum Zitat Cicek D, Kandi B, Oguz S, Cobanoglu B, Bulut S, Saral Y (2008) An urticarial vasculitis case induced by glatiramer acetate. J Dermatological Treat 19(5):305–307CrossRef Cicek D, Kandi B, Oguz S, Cobanoglu B, Bulut S, Saral Y (2008) An urticarial vasculitis case induced by glatiramer acetate. J Dermatological Treat 19(5):305–307CrossRef
45.
Zurück zum Zitat Szilasiová J, Gdovinová Z, Jautová J, Baloghová J, Ficová M, Bohuš P (2009) Cutaneous vasculitis associated with interferon β-1b treatment for multiple sclerosis. Clin Neuropharmacol 32(5):301–303PubMedCrossRef Szilasiová J, Gdovinová Z, Jautová J, Baloghová J, Ficová M, Bohuš P (2009) Cutaneous vasculitis associated with interferon β-1b treatment for multiple sclerosis. Clin Neuropharmacol 32(5):301–303PubMedCrossRef
46.
Zurück zum Zitat Horisberger A, Pantazou V, Cuendet G, Ribi C, Dunet V, Théaudin M (2020) ANCA-associated life-threatening systemic vasculitis after alemtuzumab treatment for multiple sclerosis. Multiple Scler J 26(12):1599–1602CrossRef Horisberger A, Pantazou V, Cuendet G, Ribi C, Dunet V, Théaudin M (2020) ANCA-associated life-threatening systemic vasculitis after alemtuzumab treatment for multiple sclerosis. Multiple Scler J 26(12):1599–1602CrossRef
47.
Zurück zum Zitat Schönfelder K, Schuh H, Pfister F, Krämer J, Eisenberger U, Skuljec J, Hackert J, Ruck T, Pfeuffer S, Fleischer M, Gäckler A (2021) Autoimmune glomerulonephritis in a multiple sclerosis patient after cladribine treatment. Multiple Scler J 27(12):1960–1964CrossRef Schönfelder K, Schuh H, Pfister F, Krämer J, Eisenberger U, Skuljec J, Hackert J, Ruck T, Pfeuffer S, Fleischer M, Gäckler A (2021) Autoimmune glomerulonephritis in a multiple sclerosis patient after cladribine treatment. Multiple Scler J 27(12):1960–1964CrossRef
48.
Zurück zum Zitat Henderson RD, Saltissi D, Pender MP (1998) Case report goodpasture’s syndrome associated with multiple sclerosis. Acta Neurol Scand 98(2):134–135PubMedCrossRef Henderson RD, Saltissi D, Pender MP (1998) Case report goodpasture’s syndrome associated with multiple sclerosis. Acta Neurol Scand 98(2):134–135PubMedCrossRef
49.
Zurück zum Zitat Lapointe E, Moghaddam B, Barclay K, Traboulsee AL, Neufeld P (2018) Goodpasture’s syndrome following alemtuzumab therapy in multiple sclerosis. Can J Neurol Sci 45(6):712–714PubMedCrossRef Lapointe E, Moghaddam B, Barclay K, Traboulsee AL, Neufeld P (2018) Goodpasture’s syndrome following alemtuzumab therapy in multiple sclerosis. Can J Neurol Sci 45(6):712–714PubMedCrossRef
50.
Zurück zum Zitat Meyer D, Coles A, Oyuela P, Purvis A, Margolin DH (2013) Case report of anti-glomerular basement membrane disease following alemtuzumab treatment of relapsing–remitting multiple sclerosis. Multiple Scler Relat Disorders 2(1):60–63CrossRef Meyer D, Coles A, Oyuela P, Purvis A, Margolin DH (2013) Case report of anti-glomerular basement membrane disease following alemtuzumab treatment of relapsing–remitting multiple sclerosis. Multiple Scler Relat Disorders 2(1):60–63CrossRef
51.
Zurück zum Zitat Clatworthy MR, Wallin EF, Jayne DR (2008) Anti–glomerular basement membrane disease after alemtuzumab. N Engl J Med 359(7):768–769PubMedCrossRef Clatworthy MR, Wallin EF, Jayne DR (2008) Anti–glomerular basement membrane disease after alemtuzumab. N Engl J Med 359(7):768–769PubMedCrossRef
52.
Zurück zum Zitat Coles AJ, Cox A, Le Page E, Jones J, Trip SA, Deans J, Seaman S, Miller DH, Hale G, Waldmann H, Compston DA (2006) The window of therapeutic opportunity in multiple sclerosis: evidence from monoclonal antibody therapy. J Neurol 253:98–108PubMedCrossRef Coles AJ, Cox A, Le Page E, Jones J, Trip SA, Deans J, Seaman S, Miller DH, Hale G, Waldmann H, Compston DA (2006) The window of therapeutic opportunity in multiple sclerosis: evidence from monoclonal antibody therapy. J Neurol 253:98–108PubMedCrossRef
53.
Zurück zum Zitat Scolding NJ, Jayne DR, Zajicek JP, Meyer PA, Wraight EP, Lockwood CM (1997) Cerebral vasculitis—recognition, diagnosis and management. QJM: Int J Med 90(1):61–73CrossRef Scolding NJ, Jayne DR, Zajicek JP, Meyer PA, Wraight EP, Lockwood CM (1997) Cerebral vasculitis—recognition, diagnosis and management. QJM: Int J Med 90(1):61–73CrossRef
54.
Zurück zum Zitat Kieseier BC, Hartung HP Current disease-modifying therapies in multiple sclerosis. InSeminars in neurology 2003 (Vol. 23, No. 02, pp. 133–146). Copyright© 2002 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA. Tel.:+ 1 (212) 584–4662 Kieseier BC, Hartung HP Current disease-modifying therapies in multiple sclerosis. InSeminars in neurology 2003 (Vol. 23, No. 02, pp. 133–146). Copyright© 2002 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA. Tel.:+ 1 (212) 584–4662
55.
Zurück zum Zitat Mistry N, Shapero J, Crawford RI (2009) A review of adverse cutaneous drug reactions resulting from the use of interferon and Ribavirin. Can J Gastroenterol Hepatol 23:677–683 Mistry N, Shapero J, Crawford RI (2009) A review of adverse cutaneous drug reactions resulting from the use of interferon and Ribavirin. Can J Gastroenterol Hepatol 23:677–683
56.
Zurück zum Zitat Gono T, Matsuda M, Shimojima Y, Kaneko K, Murata H, Ikeda SI (2007) Lupus erythematosus profundus (lupus panniculitis) induced by interferon-β in a multiple sclerosis patient. J Clin Neurosci 14(10):997–1000PubMedCrossRef Gono T, Matsuda M, Shimojima Y, Kaneko K, Murata H, Ikeda SI (2007) Lupus erythematosus profundus (lupus panniculitis) induced by interferon-β in a multiple sclerosis patient. J Clin Neurosci 14(10):997–1000PubMedCrossRef
58.
Zurück zum Zitat Havrdova E, Horakova D, Kovarova I (2015) Alemtuzumab in the treatment of multiple sclerosis: key clinical trial results and considerations for use. Ther Adv Neurol Disord 8(1):31–45PubMedPubMedCentralCrossRef Havrdova E, Horakova D, Kovarova I (2015) Alemtuzumab in the treatment of multiple sclerosis: key clinical trial results and considerations for use. Ther Adv Neurol Disord 8(1):31–45PubMedPubMedCentralCrossRef
60.
Zurück zum Zitat Filippi M, Rocca MA, Ciccarelli O, De Stefano N, Evangelou N, Kappos L, Rovira A, Sastre-Garriga J, Tintorè M, Frederiksen JL, Gasperini C (2016) MRI criteria for the diagnosis of multiple sclerosis: MAGNIMS consensus guidelines. Lancet Neurol 15(3):292–303PubMedPubMedCentralCrossRef Filippi M, Rocca MA, Ciccarelli O, De Stefano N, Evangelou N, Kappos L, Rovira A, Sastre-Garriga J, Tintorè M, Frederiksen JL, Gasperini C (2016) MRI criteria for the diagnosis of multiple sclerosis: MAGNIMS consensus guidelines. Lancet Neurol 15(3):292–303PubMedPubMedCentralCrossRef
Metadaten
Titel
The coincidence of multiple sclerosis and primary vasculitis; from the bench of pathology to the bedside of treatment: a systematic review of case reports
verfasst von
Melika Arab Bafrani
Hassan Asadigandomani
Naghmeh Abbasi Kasbi
Hora Heidari
Sharareh Eskandarieh
Publikationsdatum
04.09.2024
Verlag
Springer International Publishing
Erschienen in
Neurological Sciences / Ausgabe 1/2025
Print ISSN: 1590-1874
Elektronische ISSN: 1590-3478
DOI
https://doi.org/10.1007/s10072-024-07746-8

Kompaktes Leitlinien-Wissen Neurologie (Link öffnet in neuem Fenster)

Mit medbee Pocketcards schnell und sicher entscheiden.
Leitlinien-Wissen kostenlos und immer griffbereit auf ihrem Desktop, Handy oder Tablet.

Neu im Fachgebiet Neurologie

Demenz-Leitlinie aktualisiert

  • 13.03.2025
  • Demenz
  • Nachrichten

Empfohlen wird jetzt auch eine Musiktherapie sowie bei unklarem diagnostischem Befund ein Tau-PET, und Depressive mit leichten kognitiven Störungen sollten eine Verhaltenstherapie erhalten – das sind einige wichtige Änderungen der aktuellen S3-Leitlinie Demenzen.

Frauen akkumulieren Tau-Protein schneller als Männer

Frauen mit einer hohen Beta-Amyloid-Last im Gehirn aggregieren mehr Tau-Protein als Männer mit vergleichbaren Amyloidwerten. Ähnliches gilt für Frauen mit einem ApoE4-Allel. Dafür sprechen die Daten einer Metaanalyse von Menschen im präklinischen Alzheimerstadium.

Frauen mit Apoplex in Deutschland nicht benachteiligt – oder doch?

Eine Analyse von Daten des statistischen Bundesamtes spricht dafür, dass Frauen in der Schlaganfallbehandlung nicht benachteiligt sind. Im Detail bleiben aber Fragen offen.

MS-Medikamente absetzen: ab 60 Jahren eine Option

Wann können ältere MS-Kranke ihre krankheitsmodifizierende Therapie gefahrlos absetzen? Bisher lieferten kontrollierte Studien hier keine eindeutigen Antworten. Eine neue Auswertung der Studie DISCOMS deutet auf einen grenzwertigen Nutzen ab 60 Jahren.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.